登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Clinical Study of Universal CD19 CAR-γδ T Cell Infusion in the Treatment of Relapsed/Refractory Acute B Lymphoblastic Leukemia
ClinicalTrials.gov 上登记的一项B 细胞急性淋巴细胞白血病开放试验,由福建医科大学附属第一医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07491263,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 6
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(6 项)收起清单
14 岁 至 未注明;性别:不限
登记记录的入选字段
Cytology or histology confirms tumor cell immunophenotype as CD19-positive;
入选标准第 8 条
Failure to achieve CR after 2 cycles of standard chemotherapy;
入选标准第 3 条
Toxicity from prior anti-tumor therapy ≤ Grade 1 (according to CTCAE v5.0) or at an acceptable level per inclusion/exclusion criteria;
入选标准第 13 条
Pregnant or lactating women, or women who disagree to use effective contraception during treatment and within 1 year after treatment;
排除标准第 2 条
Patients who have received allogeneic immune cell therapy within 6 months before enrollment, or donor lymphocyte infusion within 6 weeks before enrollment;
排除标准第 5 条
Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2;
入选标准第 10 条
Key organ functions meeting the following criteria: left ventricular ejection fraction ≥50% by echocardiography; serum creatinine ≤1.5 × upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3 × ULN; total bilirubin ≤1.5 × ULN;
入选标准第 11 条
Negative pregnancy test for women of childbearing potential; both males and females agree to use effective contraception during treatment and for 1 year thereafter;
入选标准第 12 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);影像与可测量病灶;试验排除的其他疾病。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07491263,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Age > 14 years, gender unrestricted; Clinically diagnosed with relapsed/refractory acute B-lymphoblastic leukemia, with bone marrow blast/immature lymphocyte proportion ≥5% (morphology) (excluding cases with isolated extramedullary involvement), meeting any of the following criteria: Failure to achieve CR after 2 cycles of standard chemotherapy; Initial induction achieved CR, but CR duration ≤12 months; Relapsed/refractory B-ALL refractory to first or multiple salvage therapies; Post-hematopoietic stem cell transplantation relapse, including hematological relapse and minimal residual disease (MRD) positivity; Patients for whom no standard therapy exists. Cytology or histology confirms tumor cell immunophenotype as CD19-positive; Expected survival time exceeding 3 months; Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2; Key organ functions meeting the following criteria: left ventricular ejection fraction ≥50% by echocardiography; serum creatinine ≤1.5 × upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3 × ULN; total bilirubin ≤1.5 × ULN; Negative pregnancy test for women of childbearing potential; both males and females agree to use effective contraception during treatment and for 1 year thereafter; Toxicity from prior anti-tumor therapy ≤ Grade 1 (according to CTCAE v5.0) or at an acceptable level per inclusion/exclusion criteria; No significant hereditary diseases; Able to comprehend the trial requirements and procedures, and willing to participate in the clinical study as required; Signed informed consent form for the trial排除标准:Exclusion Criteria:
Presence of central nervous system (CNS) involvement or a clinically significant history of CNS diseases, such as epilepsy and cerebrovascular diseases; Pregnant or lactating women, or women who disagree to use effective contraception during treatment and within 1 year after treatment; Other malignancies that are not in remission; Patients with primary immunodeficiency or autoimmune diseases requiring immunosuppressive therapy; Patients who have received allogeneic immune cell therapy within 6 months before enrollment, or donor lymphocyte infusion within 6 weeks before enrollment; Confirmed positive anti-FMC63 and DSA responses in the patient's serum; Patients who have participated in other clinical trials within 4 weeks before enrollment; Uncontrolled infectious diseases or other serious conditions, including but not limited to infections (human immunodeficiency virus, acute or chronic active hepatitis B or C), congestive heart failure, unstable angina, arrhythmia, or conditions considered by the treating physician to pose unpredictable risks; History of stroke or intracranial hemorrhage within 3 months before enrollment; Major surgery or trauma within 28 days before enrollment, or main side effects not yet recovered; History of allergy to any component of the cell product; Inability to understand or unwillingness to sign the informed consent form; Other reasons deemed by the researchers as unsuitable for the clinical trial.
引自 ClinicalTrials.gov, NCT07491263, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07491263,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。